cost
associ
drugvaccin
develop
specif
pathogen
pauciti
commerci
avail
effect
prevent
therapeut
vaccin
resist
emerg
reemerg
viru
challeng
order
establish
broad
spectrum
antivir
therapeut
innov
approach
scatter
research
outcom
could
brought
togeth
one
umbrella
essenti
articl
postul
novel
hypothesi
aim
provid
guid
principl
futur
therapeut
antivir
research
underpin
examin
three
infecti
diseas
global
public
health
import
ebola
sever
acut
respiratori
syndrom
sar
dengu
viral
diseas
share
mani
featur
common
henc
insight
pathogen
featur
could
reveal
common
target
molecul
futur
antivir
develop
propos
role
master
molecul
potenti
therapeut
target
three
diseas
cascad
event
proinflammatori
respons
discuss
search
common
therapeut
target
molecul
evalu
comput
lead
suggest
possibl
novel
antivir
remedi
knowledg
first
paper
consid
multipl
emerg
infecti
diseas
evalu
common
pathway
pathogenesi
propos
prospect
antivir
target
molecul
ebola
typic
incub
period
day
follow
infect
person
develop
fever
rise
rapidli
clinic
symptom
may
includ
myalgia
nausea
vomit
andor
diarrhoea
impair
coagul
subconjunctiv
haemorrhag
bruis
defect
clot
venipunctur
site
blood
urin
faec
may
even
visibl
sever
case
patient
may
suffer
viscer
organ
necrosi
along
haemorrhag
skin
mucou
membran
typic
incub
period
sever
acut
respiratori
syndrom
coronaviru
sarscov
day
averag
durat
first
clinic
symptom
hospit
admiss
day
patient
usual
show
tenaci
fever
myalgia
malais
dri
cough
headach
dyspnoea
primari
clinic
symptom
howev
sputum
product
sore
throat
rhinorrhoea
nausea
vomit
diarrhoea
may
also
notic
minor
sign
lymphocytopenia
along
intravascular
coagul
elev
level
lactat
dehydrogenas
thrombocytopenia
bilater
viral
pneumonia
acut
respiratori
distress
syndrom
ard
common
advers
clinic
featur
sar
clinic
manifest
dengu
rang
dengu
fever
df
sever
form
like
dengu
haemorrhag
fever
dhf
sometim
dengu
shock
syndrom
dss
arthralgia
osteagia
myalgia
headach
skin
rash
common
clinic
symptom
df
persist
around
one
week
henc
common
name
breakbon
fever
sevenday
fever
four
known
dengu
viru
denv
serotyp
caus
infect
human
secondari
dengu
infect
heterotyp
serotyp
respons
primari
infect
initi
immunopatholog
phenomenon
antibodydepend
enhanc
ade
infect
may
result
dhf
dss
clinic
manifest
dhf
includ
haemorrhag
tendenc
plasma
leakag
thrombocytopenia
addit
exist
symptom
df
patient
develop
dss
exhibit
symptom
df
dhf
along
circulatori
failur
hypotens
sign
system
shock
proinflammatori
respons
follow
similar
pattern
elev
cytokin
level
pathophysiolog
ebola
character
initi
uncontrol
cytokin
storm
includ
overexpress
proand
antiinflammatori
cytokin
chemokin
free
radic
coagul
factor
ebolarel
fatal
notabl
trigger
proinflammatori
cytokin
chemokin
inabl
human
immun
system
curb
cytokin
storm
mean
neg
feedback
loop
result
signific
tissu
organ
damag
frequent
lead
case
fatal
onset
ebolaviru
ebov
infect
rna
polymeras
cofactor
inhibit
interferon
respons
first
line
antivir
defenc
antagon
type
interferon
respons
believ
disrupt
type
type
interferon
respons
also
capabl
inhibit
dc
matur
initi
subsequ
proinflammatori
respons
immatur
dc
activ
macrophag
produc
play
major
role
inflammatori
respons
promot
migrat
immun
cell
activ
apoptosi
caspas
rais
level
observ
fatal
case
ebola
also
disrupt
endotheli
barrier
caus
cell
leakag
clinic
laboratori
test
perform
sever
research
group
sampl
isol
ebolainfect
patient
remark
west
african
epidem
show
substanti
immun
activ
correl
excess
inflammatori
respons
increas
number
activ
plasmablast
cell
cell
observ
infect
case
compar
healthi
control
individu
significantli
higher
level
proinflammatori
cytokin
chemokin
detect
fatal
case
compar
nonfat
case
analysi
anim
model
reveal
profound
upregul
interferonstimul
gene
isg
earli
stage
infect
cytotox
tlymphocyteassoci
protein
express
cell
detect
markedli
higher
level
nonsurviv
patient
program
cell
death
protein
concentr
found
much
higher
fatal
case
compar
survivor
protein
play
role
regul
cell
homeostasi
elev
express
correl
cell
function
exhaust
well
poor
viral
clearanc
sarscov
infect
remark
overexpress
cytokin
chemokin
diseas
sever
correl
product
massiv
cytokin
storm
lung
infiltr
monocyt
macrophag
deplet
lymphocyt
popul
studi
reveal
host
fatal
fact
relat
sarscov
viru
replic
virusinduc
unregul
immun
respons
histolog
examin
mous
model
sar
two
day
postinfect
show
high
viral
titr
increas
presenc
macrophag
tlymphocyt
focal
perivascular
infiltr
within
lung
along
heighten
immun
cell
activ
bronchiolar
epitheli
necrosi
lumin
necrot
debri
also
visibl
migrat
plasmacytoid
dc
inflammatori
cell
nk
cell
nk
cell
macrophag
cell
lung
observ
earli
stage
infect
signific
elev
inflammatori
cytokin
chemokin
level
also
detect
earli
infect
compar
healthi
control
group
cell
neutrophil
found
migrat
lung
late
stage
infect
infect
denv
activ
innat
immun
system
host
vitro
investig
reveal
increas
proinflammatori
cytokin
upon
infect
denv
protein
induc
infect
macrophag
endotheli
cell
produc
rang
proinflammatori
cytokin
includ
mif
mcp
rant
mediat
increas
permeabl
play
role
inflamm
plasma
leakag
vivo
infect
dc
produc
facilit
dc
migrat
lymph
node
increas
level
type
ifn
posit
correl
viral
protein
express
one
studi
cytokin
dengu
infect
express
innat
adapt
immun
cell
rais
level
report
particularli
dhf
case
plasma
leakag
coagulopathi
two
way
play
role
diseas
sever
elev
observ
late
infect
indic
activ
treg
cell
respons
preced
cytokin
storm
histopatholog
examin
sampl
infect
patient
shown
pronounc
immun
activ
specif
organ
monocyt
macrophag
dc
major
site
denv
infect
replic
signific
increas
lymphocyt
may
detect
fatal
denv
case
compar
nonfat
group
investig
reveal
notabl
rise
cell
produc
inflammatori
cytokin
liver
infect
patient
presenc
nuclear
vacuolar
degener
swollen
mitochondria
infect
case
also
indic
mechan
involv
cell
death
lung
tissu
sampl
fatal
case
show
sever
damag
character
increas
cellular
presenc
mononuclear
inflammatori
infiltr
hyperplasia
alveolar
macrophag
histopatholog
ultrastructur
analysi
heart
kidney
spleen
detect
damag
target
organ
denvinfect
patient
damag
healthi
sampl
quantif
analysi
reveal
presenc
lymphocyt
inflammatori
cytokin
chemokin
concentr
mani
fold
higher
normal
signific
involv
apoptosi
also
detect
target
organ
biopsi
fatal
case
three
viral
infect
describ
share
common
featur
establish
cytokin
storm
well
lead
pathogen
outcom
follow
primari
exposur
antigen
innat
immun
act
first
line
defenc
studi
reveal
monocytemacrophag
dc
infiltr
earli
site
infect
viru
replic
immun
cell
contain
viru
particl
later
migrat
organ
tissu
order
evad
innat
immun
respons
viru
must
inhibit
interferon
respons
analysi
vitro
vivo
model
strongli
suggest
ebov
sarscov
denv
abl
evad
ifn
respons
order
establish
infect
viral
entri
infect
character
express
extrem
high
level
proinflammatori
cytokin
chemokin
lymphocyt
excess
provok
cytokin
storm
respons
plasma
leakag
vascular
permeabl
dissemin
intravascular
coagul
dic
well
defect
adapt
immun
pathophysiolog
event
enabl
effici
dissemin
viru
provid
metabol
milieu
fatal
outcom
may
result
apoptosi
lymphocyt
facilit
diseaserel
mortal
multipl
vivo
studi
report
massiv
level
lymphocyt
apoptosi
three
infect
lymphocytopenia
commonli
observ
among
fatal
absent
survivor
focus
key
mediat
involv
proinflammatori
respons
help
identifi
common
target
molecul
potenti
therapeut
interest
among
differ
proinflammatori
cytokin
caught
cytokin
storm
primari
interest
role
transit
cytokin
may
consid
master
cytokin
chang
natur
serv
proand
antiinflammatori
besid
respons
bridg
gap
innat
adapt
arm
immun
respons
view
logic
step
review
characterist
dual
role
well
determin
perform
may
trigger
infect
condit
thu
focu
function
follow
section
discuss
keyston
cytokin
contribut
infect
immun
flip
side
also
merit
attent
antiinflammatori
cytokin
excess
express
almost
fatal
case
viral
infect
level
becom
mani
fold
higher
detect
survivor
specul
act
homeostasi
involv
counterregul
proinflammatori
immun
respons
cytokin
environ
becom
extrem
howev
role
remain
unclear
extens
investig
requir
unravel
complex
mechan
involv
research
particularli
interest
dissect
pathway
trigger
cytokin
storm
phenomenon
understand
subsequ
cellular
event
relat
diseas
fatal
base
hypothesi
aim
explain
concentr
elev
viral
infect
fatal
sustain
elev
level
fatal
case
viral
infect
earmark
import
molecul
investig
recent
year
consid
keyston
cytokin
health
diseas
due
pleiotrop
characterist
uniqu
abil
function
proand
antiinflammatori
respons
depend
specif
condit
light
decis
role
cytokin
stormmedi
immunopathogenesi
provid
princip
focu
reviewnot
regard
regul
immun
reactiv
way
relat
diseas
fatal
signal
start
bind
receptor
complex
associ
exist
two
differ
form
membranebound
receptor
solubl
receptor
membranebound
receptor
becom
solubl
shed
differenti
splice
former
one
frequent
event
depend
receptor
state
signal
may
either
two
type
classic
signal
transsign
classic
signal
requir
bind
membranebound
wherea
transsign
start
bind
transsign
proinflammatori
classic
signal
antiinflammatori
natur
detail
mechan
beyond
scope
review
instead
focu
involv
two
differ
form
immunopathogenesi
pioneer
cytokin
initi
proinflammatori
respons
infect
transsign
correl
posit
increas
product
proinflammatori
cytokin
chemokin
includ
tnf
mcsf
acth
cortisol
transsign
also
shown
initi
monocyt
macrophag
differenti
attract
immun
cell
also
suppress
reg
cell
addit
transsign
involv
progress
manifest
autoimmun
diseas
switch
two
differ
form
depend
concentr
normal
physiolog
condit
plasma
level
minut
rang
pg
ml
detect
ngml
therefor
steadi
state
concentr
time
higher
inflamm
howev
level
may
increas
million
fold
wherea
rise
typic
fold
challeng
antigen
upon
secret
first
bind
initi
proinflammatori
respons
howev
level
exceed
bind
therebi
trigger
antiinflammatori
respons
thu
order
maintain
sustain
proinflammatori
respons
therebi
block
antiinflammatori
respons
system
concentr
must
higher
observ
select
block
transsign
rather
global
blockad
effect
mean
rescu
mous
model
possibl
death
henc
may
consid
immunoregulatori
master
molecul
control
govern
pathogen
outcom
yet
still
mani
question
surround
mechan
action
need
answer
even
held
respons
escal
rate
fatal
theoret
least
elev
concentr
eventu
suppress
level
therebi
facilit
switch
back
antiinflammatori
respons
viral
infect
howev
quit
opposit
observ
fatal
case
suggest
complex
mechan
behind
phenomenon
concentr
somehow
remain
high
entir
period
infect
therebi
establish
persist
proinflammatori
respons
via
transsign
thu
reason
presum
biomolecul
interact
process
influenc
sustain
transsign
result
cytokin
stormmedi
fatal
sinc
discoveri
commonli
known
tumour
necrosi
factor
tnf
convert
enzym
drawn
enorm
interest
potenti
therapeut
target
multipl
diseas
pathway
close
associ
inflammatori
cytokin
found
upregul
transcript
express
research
propos
releas
membranebound
precursor
solubl
form
facilit
inflammatori
process
relev
believ
master
molecul
may
explain
uncontrol
transsign
increas
proinflammatori
respons
infect
key
protein
respons
membranebound
shed
thu
product
apoptosi
shown
act
natur
stimulu
shed
surfac
neutrophil
therebi
contribut
proinflammatori
transsign
respons
uncontrol
transsign
could
also
explain
mechan
pictur
infect
worsen
envisag
infect
order
maintain
homeostasi
product
inflammatori
cytokin
follow
counter
releas
antiinflammatori
cytokin
increas
level
plasma
glucocorticoid
cortisol
also
reduc
absolut
number
lymphocyt
lymphocyt
loss
observ
pathogenesi
mediat
sole
apoptot
machineri
also
involv
necrosi
nonapoptot
form
cell
death
event
mediat
elev
level
phenomenon
explain
antiinflammatori
cortisol
level
remain
high
alongsid
lymphocytopenia
fatal
case
detail
mechan
lymphocyt
loss
yet
understood
though
believ
multipl
mediat
fasfasl
relat
apoptosisinduc
ligand
trail
proapoptot
gene
bim
bid
trigger
play
pivot
role
type
cell
death
interact
mediat
report
sever
studi
show
activ
neutrophil
loss
proce
gener
cleav
propos
mechan
level
remain
higher
throughout
infect
explain
skip
cissign
pathway
event
ultim
disrupt
balanc
proand
antiinflammatori
respons
establish
transsign
mediat
persist
proinflammatori
respons
direct
evid
apoptosi
presenc
pharmacolog
inhibitor
restrict
shed
henc
postul
detect
viral
infect
initi
proinflammatori
respons
via
transsign
pathway
consequ
proinflammatori
cytokin
level
rise
concentr
cortisol
also
increas
gradual
order
maintain
homeostasi
activ
apoptot
mechan
part
neg
feedback
loop
combin
cell
death
lymphocytopenia
stimul
shed
proteolysi
subsequ
level
also
increas
bypass
classicsign
result
uncontrol
transsignalingmedi
inflammatori
respons
prevail
fig
case
therefor
infect
proce
fatal
outcom
abil
control
influenc
molecul
immun
system
subject
extens
investig
well
establish
mediat
shed
cell
surfac
molecul
involv
progress
multipl
patholog
condit
transsignalingmedi
pathogenesi
known
common
featur
inflammatori
bowel
diseas
well
mani
respiratori
diseas
henc
develop
select
inhibitor
challeng
sever
inhibitor
test
therapeut
candid
sever
year
pharmaceut
compani
like
british
biotech
chemicon
glaxo
smithklin
gsk
pfizer
wyeth
also
conduct
research
inhibitor
aim
develop
therapeut
rheumatoid
arthriti
inhibitor
like
develop
british
biotech
gsk
wyeth
incyt
corp
discontinu
due
achiev
target
promis
inhibitor
fail
meet
potenti
low
efficaci
toxic
undesir
side
effect
mostli
due
inhibit
multipl
proteas
target
specif
shed
event
knowledg
gap
vivo
vitro
studi
also
contribut
fail
inhibitor
design
vitro
alway
show
anticip
effect
desir
efficaci
vivo
sinc
whole
organ
consid
multipl
pharmacokinet
factor
come
play
vivo
detect
vitro
studi
addit
understand
biolog
incomplet
new
research
therefor
aim
select
block
target
inhibitor
higher
specif
order
increas
efficaci
diminish
side
effect
type
select
inhibitor
design
affect
specifi
target
subset
inhibit
specif
shed
event
driven
discuss
also
appear
develop
select
inhibitor
arrest
product
inhibit
shed
inhibit
may
result
suppress
transsignalingmedi
proinflammatori
respons
initi
classicalsignalingmedi
antiinflammatori
respons
therebi
balanc
elev
cytokin
level
thu
reduc
diseas
pathogen
select
inhibitor
prevent
shed
block
shed
event
induc
accord
hypothesi
gener
new
inhibit
may
possibl
stop
unregul
transsignalingmedi
proinflammatori
respons
studi
murin
model
also
suggest
inhibit
transsign
increas
surviv
though
failur
previou
inhibitor
may
discourag
drug
compani
invest
develop
select
inhibitor
target
highli
select
inhibitor
still
attract
promis
approach
research
similar
mechan
work
select
viral
infect
inhibitor
show
potenti
futur
trial
also
bring
great
relief
infect
patient
well
might
possibl
develop
singl
therapeut
molecul
effect
multipl
viral
diseas
although
long
way
go
achiev
commerci
realiz
proposit
novel
hypothesi
provid
new
dimens
futur
antivir
research
broad
rang
antivir
cure
also
easili
afford
global
bioinformat
comput
biolog
tool
abl
reveal
complex
bimolecular
interact
therebi
systemat
integr
knowledg
tradit
reductionist
approach
biomolecular
conundrum
approach
recent
use
decod
enigma
diseaseassoci
pathway
review
base
hypothesi
describ
pursu
comput
biolog
approach
target
sever
key
proand
antiinflammatori
molecul
tnf
fa
faslfaslg
aim
develop
interact
network
among
molecul
use
two
interact
databas
string
genemania
build
visual
interconnected
undertak
analysi
consid
import
proinflammatori
cytokin
commonli
found
fatal
case
close
associ
therefor
also
taken
consider
addit
includ
due
instrument
function
determin
pathogen
fate
via
differenti
signal
glucocorticoid
receptor
repres
antiinflammatori
regul
tnf
fa
fasl
trail
select
role
antiinflammatori
regul
process
apoptosi
final
chosen
virtu
pivot
role
signal
regul
immunopathogenesi
describ
earlier
construct
interactom
ppi
network
use
string
databas
set
minimum
requir
interact
score
medium
confid
level
maximum
number
interactor
report
shell
leav
paramet
default
valu
result
huge
complex
network
hairbal
remodel
cytoscap
fig
insight
observ
complex
network
show
three
crucial
interactor
nfkb
among
molecul
network
three
exert
magisteri
regul
previous
select
molecul
act
directli
whistleblow
sever
research
group
previous
report
regulatori
role
nfkb
select
target
molecul
nfkb
believ
key
regul
express
upon
infect
stimul
tlr
ligand
macrophag
activ
notch
signal
upregul
product
well
initi
inflammatori
respons
notch
mediat
upregul
control
nfkb
well
interestingli
notch
signal
activ
aim
reconstruct
previou
network
integr
three
molecul
key
target
set
use
default
paramet
string
genemania
newli
construct
network
depict
fig
b
show
interact
target
molecul
comprehens
way
enabl
better
understand
influenc
understood
easili
network
describ
postul
addit
construct
anoth
network
fig
genemania
show
direct
interact
key
regulatori
molecul
tnf
network
influenc
regulatori
molecul
easili
understood
recent
studi
therapeut
develop
demonstr
inhibit
downregul
notch
signal
henc
rapid
screen
molecular
interact
form
targetspecif
cluster
resolv
stochast
natur
larg
number
molecul
complex
network
uncov
studi
may
consid
potenti
drug
target
form
basi
broad
rang
therapeut
approach
corticosteroid
potent
suppressor
inflammatori
respons
therefor
use
antivir
treatment
divers
infecti
diseas
well
target
viral
infect
studi
focus
propos
potent
antivir
target
multipl
diseas
current
statu
limit
corticosteroid
major
consider
help
establish
corticosteroid
consid
suitabl
broad
rang
antivir
therapeut
address
exist
obtain
string
databas
remodel
use
cytoscap
along
mention
key
proand
antiinflammatori
molecul
total
highlight
cadetblu
node
rest
depict
orang
node
among
key
molecul
nine
tnf
fa
faslfaslg
connect
red
edg
rest
connect
blue
edg
eas
reader
understand
confid
score
set
medium
maximum
number
interactor
report
set
shell
gener
interactom
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
drawback
also
gain
idea
select
block
might
form
basi
effect
treatment
propos
although
immunosuppress
corticosteroid
drug
commonli
use
attempt
reduc
fatal
rate
result
clinic
trial
suffici
satisfactori
approv
effect
class
therapeut
corticosteroid
believ
reduc
concentr
proinflammatori
cytokin
upregul
antiinflammatori
mediat
inhibit
transcript
effect
nfkb
recent
year
type
inhibit
becom
less
popular
therapeut
intervent
due
combin
sideeffect
glucocorticoid
treatment
global
inhibit
nfkb
one
frequent
use
corticosteroid
drug
dexamethason
state
case
report
less
effect
glucocorticoidmedi
stimul
hypothalamicpituitaryadren
axi
also
drive
lymphocytopenia
may
promot
exagger
proinflammatori
respons
eventu
caus
worsen
pathogen
condit
due
concern
regard
sideeffect
world
health
organ
present
recommend
glucocorticoid
treatment
furthermor
known
effect
corticosteroid
treatment
greatli
depend
time
drug
administr
addit
genet
makeup
individu
contribut
therapeut
efficaci
therefor
becom
extrem
challeng
determin
appropri
cours
drug
administr
patient
despit
widespread
avail
corticosteroidbas
common
therapeut
strategi
mani
molecul
propos
antivir
candid
ebola
sarscov
dengu
prove
effect
experiment
model
clinic
trial
recent
silico
studi
suggest
ibuprofen
nonsteroid
compound
promis
antivir
target
ebola
infect
favipiravir
pyrazinecarboxamid
deriv
effect
aerosol
ebola
viru
infect
immunodefici
alphabeta
interferon
receptor
knockout
ifnar
mice
phase
ii
trial
favipiravir
ebov
also
complet
guinea
novemb
howev
preliminari
find
suggest
signific
relationship
favipiravir
ebov
viral
kinet
fail
achiev
result
predict
outset
trial
brincidofovir
lipidconjug
analogu
cidofovir
given
ebov
patient
emerg
treatment
effect
brincidofovir
ebov
still
discern
clinic
anim
vitro
data
current
withheld
ribavirin
frequent
use
drug
combat
sarscov
administ
togeth
corticosteroid
combin
immunoglobulin
thymosin
also
use
stimul
cell
sarsinfect
individu
sometim
use
combin
regimen
ribavirin
although
benefici
effect
therapi
fulli
understood
proteas
inhibitor
lopinavir
ritonavir
may
lead
improv
outcom
sar
patient
use
combin
ribavirin
therapeut
trial
dengu
also
prove
disappoint
conduct
two
differ
antivir
candid
balapiravir
celgosivir
vietnam
singapor
respect
fail
provid
benefici
outcom
denv
infect
chloroquin
show
promis
antivir
potenti
vitro
experi
subsequ
clinic
trial
fail
reduc
viraemia
adult
dengu
patient
lovastatin
shown
increas
surviv
anim
model
interrupt
denv
assembl
pathway
howev
prove
effect
human
review
provid
plausibl
hypothesi
understand
molecular
basi
select
major
infecti
diseas
ebola
sar
dengu
furthermor
draw
upon
empir
data
propos
design
put
appropri
therapeut
built
framework
might
help
overcom
present
knowledg
gap
surround
phenomenon
immun
hyperstimulationmedi
fatal
envisag
near
futur
groundbreak
transform
research
direct
may
possibl
base
hypothesi
util
comput
model
analys
vast
volum
publicli
access
data
systemat
approach
understand
variou
infecti
diseas
episod
achiev
inform
may
consider
valu
enabl
research
develop
experiment
model
test
novel
antivir
therapeut
design
howev
also
acknowledg
due
unavail
sizabl
amount
interactom
data
comput
studi
review
highlight
sever
intrins
limit
sinc
anim
reservoir
host
mimic
pathogenesi
human
specif
virus
difficult
develop
suitabl
vivo
model
exploit
order
dissect
pathogen
event
therebi
achiev
hypothes
outcom
furthermor
anim
reservoir
may
becom
infect
discuss
virus
develop
clinic
symptom
reservoir
host
uniqu
immun
mechan
maintain
diseas
free
state
virus
pose
anoth
crucial
question
diseasefre
state
maintain
could
cure
found
investig
reservoir
anim
host
understand
mechan
reservoir
show
clinic
symptom
like
human
virus
may
help
us
find
uniqu
natur
mechan
contribut
type
knowledg
could
lead
us
shape
vivo
studi
well
improv
knowledg
gap
vitro
vivo
lot
challeng
studi
reservoir
host
natur
condit
mimick
natur
habitat
need
huge
logist
support
also
involv
great
cost
thu
long
way
achiev
answer
reservoir
host
work
restrict
understand
pathogen
event
human
therefor
intend
explain
diseasefre
state
reservoir
anim
host
spite
acknowledg
limit
type
comput
model
analysi
could
shape
futur
antivir
research
narrow
target
logic
explan
ration
hypothesi
proposit
outcom
numer
research
studi
perform
around
world
known
analys
collect
regard
possibl
explor
new
possibl
bring
togeth
consider
bodi
exist
data
singl
analyt
space
condit
work
consid
pathogen
event
multipl
diseas
order
establish
sequenti
framework
find
possibl
nexu
metabol
regul
explain
pathogen
event
progress
fatal
outcom
transsign
pathway
profoundli
influenc
summari
propos
possibl
antivir
target
success
regul
transsign
junction
achiev
may
possibl
keep
check
otherwis
uncontrol
proinflammatori
respons
common
clinic
featur
viral
infect
consid
type
immunopatholog
regul
may
prove
success
prevent
death
ebola
sar
dengu
infect
may
similarli
play
critic
role
combat
human
infecti
diseas
author
declar
actual
potenti
conflict
interest
relat
articl
articl
contain
studi
human
anim
subject
perform
author
